Physician profile
Glen E Hall
NPI 1285670810
$4,258.67
in general payments reported to CMS, 2019-2025
29 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $12.78 · 2021: $52.88 · 2022: $764 · 2023: $937 · 2024: $1,444 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.54 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $697.37 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $578.65 | 2022-2025 | |
| Novo Nordisk INC | $547.69 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $436.00 | 2019-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $275.16 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Abbvie INC. | $224.99 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.59 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $176.14 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $145.30 | 2019-2024 | Rexulti |
| Silk Road Medical, INC. | $119.31 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Amgen INC. | $117.63 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $109.71 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.87 | 2019-2025 | Ofev, Jardiance |
| Phathom Pharmaceuticals, INC. | $76.03 | 2025 | Voquezna |
| Astellas Pharma US INC | $71.69 | 2024-2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $67.98 | 2024-2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $67.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $52.92 | 2024-2025 | Airsupra, Enhertu |
| Exact Sciences Corporation | $44.15 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $27.50 | 2025 | Eluvia |
| Cook Medical LLC | $20.63 | 2024 | Zenith |
| Eisai INC. | $19.44 | 2025 | |
| Lifescan, INC. | $19.34 | 2022 | |
| Abbott Laboratories | $18.35 | 2025 | Eterna |
| Daiichi Sankyo INC. | $16.25 | 2022 | |
| Insmed, INC. | $16.24 | 2023 | Arikayce |
| Welch Allyn | $12.78 | 2020 | |
| Medtronic, INC. | $12.67 | 2021 | |
| Inogen, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.